(Q46974867)

English

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

scientific article published on 27 December 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Aviva Joseph

1

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Noga Itskovitz-Cooper

2

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Sarit Samira

3

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Orli Flasterstein

4

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Hagit Eliyahu

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Dmitri Simberg

6

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Itzik Goldwaser

7

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Yechezkel Barenholz

8

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Eli Kedar

9

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

language of work or name

0 references

publication date

27 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

number of pages

17

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

24

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

18

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

3990-4006

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Experience with registered mucosal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Mucosal immunity and tolerance: relevance to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Recent advances in mucosal vaccines and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Bacterial toxins as tools for mucosal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Influenza vaccines: present and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Liposomes as immunological adjuvants and vaccine carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Vaccine entrapment in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunogenicity of new virosome influenza vaccine in elderly people

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A role for liposomes in genetic vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

DOTAP (and other cationic lipids): chemistry, biophysics, and transfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cationic lipids for transfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Characterization of membrane proteins in detergent solutions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Determination of total protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Intranasal immunization against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Polymeric lamellar substrate particles for intranasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Oral vaccination with immune stimulating complexes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Immunostimulating complexes (ISCOMs) for nasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Chitosan as a novel nasal delivery system for vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

CpG DNA as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Oxidised mannan as a novel adjuvant inducing mucosal IgA production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cytokines as adjuvants for the induction of mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Microparticles as vaccine adjuvants and delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Antigen delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cationic liposome-mediated enhanced generation of human HLA-restricted RSV-specific CD8+ CTL+.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Cationic liposomes induce macrophage apoptosis through mitochondrial pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Death-defying immunity: do apoptotic cells influence antigen processing and presentation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Exploiting M cells for drug and vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Anti-inflammatory activity of cationic lipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Polycationic lipids inhibit the pro-inflammatory response to LPS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Current status of live attenuated influenza virus vaccine in the US.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.12.017

7 January 2021

Identifiers

10.1016/J.VACCINE.2005.12.017

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/16516356

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46974867&oldid=2184275475"